ESR2 and prostate carcinoma: The authors also show by in vitro functional studies that the T:E fusion expression can be modulated by some ER ligands in T:E-positive NCI-H660 and VCaP cells, and hypothesize that the T:E expression can be down-regulated by an ERβ-dependent mechanism in prostate cancer cells.